Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics

Bioanalysis

Volumn 5, Issue 2, 2013, Pages 201-226

  Kaur, Surinder ^a   Xu, Keyang ^a   Saad, Ola M ^a   Dere, Randall C ^a   Carrasco Triguero, Montserrat ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; BRENTUXIMAB VEDOTIN; CYTOTOXIC AGENT; DRUG METABOLITE; IMMUNOGLOBULIN G1 ANTIBODY; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; PROSTATE ANTIGEN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1 MONOCLONAL ANTIBODY; TRASTUZUMAB EMTANSINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; BIOASSAY; BLOOD ANALYSIS; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; QUANTITATIVE ANALYSIS; REVIEW;

ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; BIOTRANSFORMATION; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES;

EID: 84872957381     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.299     Document Type: Review

References (54)

1. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. 5, 543-549 (2005). (Pubitemid 41258574)
2. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-1146 (2005). n Informative review of challenges and opportunities for antibody-drug conjugates (ADCs). (Pubitemid 41486395)
3. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14(4), 529-537 (2010).
4. Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490-1496 (2001). (Pubitemid 32708610)
5. Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell 3, 207-212 (2003). (Pubitemid 37443876)
6. Polakis P. Arming antibodies for cancer therapy. Curr. Opin. Pharmacol. 5, 382-387 (2005). (Pubitemid 40932040)
7. Teicher, BA Chari, RV. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 17, 6389-6397 (2011).
8. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 14(3), 154-169 (2008).
9. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drug as cancer therapeutics. Nat. Rev. Drug Discov. 5, 147-159 (2006).
10. Junutula JR, Raab H, Clark S et al. Sitespecific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925-932 (2008). nn Novel conjugation approach by conjugation at engineered cysteine residues resulting in homogeneous ADCs.
11. Junutula JR, Bhakta S, Raab H et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 332, 41-52 (2008).
12. Hamann PR, Hinman LM, Hollander et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-clicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13, 47-58 (2002). (Pubitemid 34119634)
13. Dijoseph JF, Armellino DC, Boghaert ER et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for treatment of B-lymphoid malignancies. Blood 103, 1807-1814 (2004). (Pubitemid 38268977)
14. Doronina SO, Toki BE, Torgov MY et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-754 (2003).
15. Doronina SO, Mendelsohn BA, Bovee TD et al. Enhance activity of monomethylauristatin F through monoclonal antibody delivery: effect of linker technology on efficacy and toxicity. Bioconjug. Chem. 17, 114-124 (2006). (Pubitemid 43157592)
16. Erickson HK, Park PU, Widdison WC et al. Antibody-maytansinoid conjugates are activated in target cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426-4433 (2006).
17. Erickson HK, Widdison WC, Mayo MF et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug. Chem. 21(1), 84-92 (2010).
18. Chari RVJ. Targeted cancer therapy:conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41, 98-107 (2008).
19. Xu K, Liu L, Saad OM et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary LC-MS. Anal. Biochem. 412, 56-66 (2011). n Novel method to measure molecular masses and relative abundances of antibody-drug conjugate drug-to-antibody ratios in biological fluids by affinity capture followed by capillary LC-MS with ESI.
20. Shen BQ, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody conjugates. Nat. Biotechnol. 30, 184-189 (2012). nn Comparison of stability of ADCs with sitespecific conjugation using affinity capture capillary LC-MS showed the site of conjugation has a significant impact on linker stability. The molecular mechanisms of deconjugation were further described based on changes in ADC molecular masses observed in vivo.
21. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody-drug conjugates Pharm. Res. 29, 2354-2366 (2012).
22. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 8, 871-874 (1971).
23. Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin. Chem. 51, 2415-2418 (2005). (Pubitemid 41692603)
24. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003). (Pubitemid 37449466)
25. Ezan E, Dubois M, Bscher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 134, 825-834 (2009).
26. Francisco JA, Cerveny CG, Meyer DL et al. cAC10-Val-CitMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective anti-tumor activity. Blood 102, 1458-1465 (2003). (Pubitemid 36988057)
27. Sanderson RJ, Hering MA, James SF et al. In vivo drug-linker stability of anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11, 843-852 (2005). (Pubitemid 40116913)
28. Tolcher AW, Ochoa L, Hammond LA et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a Phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 21, 211-222 (2003). (Pubitemid 46606149)
29. Stephan JP, Kozak KR, Wong WL. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 3(6), 677-700 (2011).
30. Hamblett KJ, Senter PD, Chace DF et al. Effects of drug loading on the anti-tumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-7070 (2004). (Pubitemid 39383058)
31. Buckwalter M, Dowell JA, Bradley JK, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J. Clin. Pharmacol. 44, 873-880 (2004). (Pubitemid 38971569)
32. Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333, 1-9 (2008).
33. US FDA. Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. US Department of Health and Human Services (2009).
34. European Medicines Agency. Draft Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use. Committee for Medicinal Products for Human Use (2010).
35. Carrasco-triguero M, Mahood C, Milojic-Blair M et al. Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic. Bioanalysis 4(16), 2013-2026 (2012).
36. Valliere-Douglass JF, McFee WA, Salas-Solano O. Native intact determination of antibodies conjugated with monomethyl auristatin E and F at interchain systeine residues. Anal. Chem. 84, 2843-2849 (2012).
37. Alley SC, Benjamin DR, Jeffrey SC et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 19, 759-765 (2008). (Pubitemid 351431408)
38. Li H, Ortiz R, Tran L et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal. Chem. 84, 1267-1273 (2012).
39. Shen BQ, Bumbaca D, Saad O et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine: an emphasis on preclinical and clinical catabolism. Curr. Drug Metab. 13, 901-910 (2012).
40. Girish S, Gupta M, Wang B et al. Clinical pharmacology of T-DM1: a novel anti-bodydrug conjugate (ADC) in development for the treatment of HER2-positive (HER2+) cancer. Cancer Chemother. Pharmacol. 69(5), 1229-1240 (2012).
41. Shankar G, Devanarayan V, Amaravidi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48, 267-281 (2008).
42. Burris HA 3rd, Rugo HS, Vukelja SJ et al. Phase II study of the antibody-drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29, 398-405 (2011).
43. Blattler WA, Chari RV. Drugs to enhance the therapeutic potency of anticancer antibodies: antibody-drug conjugates as tumor-activated prodrugs. In: Anticancer Agents-Frontiers in Cancer Chemotherapy. Ojima I, Vite G, Altmann K (Eds). American Chemical Society, Washington, DC, USA, 317-338 (2001).
44. Cassady JM, Chan KK, Floss HG, Leistner E. Recent developments in the maytansinoid antitumor agents. Chem. Pharm. Bull. (Tokyo) 52, 1-26 (2004). (Pubitemid 41685545)
45. Widdison WC, Wilhelm SD, Cavanagh EE et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 49, 4392-4408 (2006). (Pubitemid 44036683)
46. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290 (2008).
47. Krop IE, Beeram M., Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28(16), 2698-2704 (2010).
48. Leipold D, Bender B, Xu K, Theil FP, Tibbitts J. Understanding the de-conjugation of trastuzumab-MCC-DM1 through application of a multi-compartmental model of individual drug-to-antibody species in cynomolgus monkey. Presented at: American Association for Cancer Research Annual Meeting. Denver, CO, USA, 18-22 April 2009.
49. Hubert RS, Vivanco I, Chen E et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc. Natl Acad. Sci. USA 96, 14523-14528 (1999). (Pubitemid 30000683)
50. Challita-Eid P M, Morrison K, Etessami S et al. Monoclonal antibodies to sixtransmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res. 67, 5798-5805 (2007). (Pubitemid 46985013)
51. Boswell A, Mundo EE, Zhang C et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibodydrug conjugates in rats. Bioconjug. Chem. 22, 1994-2004 (2011).
52. DiJoseph JF, Goad ME, Dougher MM et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin. Cancer Res. 10(24), 8620-8629 (2004). (Pubitemid 40053430)
53. Wahl AF, Klussman K, Thompson JD et al. The anti-CD30 monoclonal antibody SGN-promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 62(13), 3736-3742 (2002). (Pubitemid 34728855)
54. Ojima I, Geng X, Wu X et al. Tumor-specific novel taxoid-monoclonal antibody conjugates. J. Med. Chem. 45(26), 5620-5623 (2002). (Pubitemid 35453753)